ClinicalTrials.gg

Program

tunlucabtagene autoleucel

Its studies are mostly in Multiple Myeloma, led by Bristol-Myers Squibb.

Furthest: phase 1, since Nov 22, 20231 company-led study, 1 open or runningNext primary completion: May 2, 2030 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bristol-Myers Squibb11 open or runningphase 1since Nov 22, 2023Nov 22, 2023May 2, 2030phase 1 · NCT06153251
  • Named in Bristol-Myers Squibb’s own pipeline as tunlu-cel, phase 1, as of Oct 29, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 22, 2023First study: phase 1 study in Multiple MyelomaFirst studyNCT06153251 · 187 planned · United States, France, Germany and more

Ahead

  1. May 2, 2030Primary completion: phase 1 study in Multiple MyelomaNCT06153251

TargetBeta

“A preparation of T-lymphocytes engineered to express chimeric antigen receptor(s) (CAR) targeting the human tumor-associated antigens (TAAs) B-cell maturation antigen (BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein coupled receptor family C group 5 member D (G…”NCIt, read by Claude

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
ramantamigJohnson & Johnsonphase 38
GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003ruleInnovent Biologicsphase 34

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06153251Multiple Myeloma · United States, France, Germany and more1RecruitingMay 2, 2030187

How it is read

Names in the registry

  • “BMS-986453”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.